INTRODUCTION {#s1}
============

Improved knowledge of the underlying molecular mechanisms involved in the pathogenesis of immune-mediated inflammatory diseases resulted in novel-targeted biologic therapies, which greatly advanced psoriasis care over the last decade. Currently registered biologics for psoriasis include the tumor necrosis factor inhibitors adalimumab, infliximab and etanercept, the interleukin (IL)-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-12/IL-23 inhibitor ustekinumab, and p19/IL-23 inhibitor guselkumab. Although they all inhibit proinflammatory cytokines, they differ in composition, efficacy, and their pharmacokinetic and pharmacodynamic behavior. For more than a decade now, physicians have used standard recommended dosing regimens to treat psoriasis patients resulting in remarkable improvements in psoriasis treatment outcomes.^[@R1]--[@R3]^ However, some patients fail to achieve desired outcomes or fail to maintain improvement over time.^[@R4]^ Various theories have been investigated elaborately to address this problem, including immunogenicity.^[@R5]--[@R7]^ Available evidence demonstrates that antiadalimumab and anti-infliximab antibodies are associated with a decreased treatment response. However, the significance of antiustekinumab antibodies (AUA) is less clear.^[@R8],[@R9]^

Other factors that might contribute to loss of response include patient or disease factors (such as extent and severity or body weight) that lead to variable serum concentrations among patients over time.^[@R10]^ Recently, we have proposed a therapeutic range for adalimumab, based on a significant association between clinical response \[Psoriasis Area and Severity Index (PASI)\] and serum trough concentrations.^[@R11]^ The defined therapeutic range suggested that a third of the patients were actually overtreated, which may lead to unnecessary higher costs and increased risk of adverse events.^[@R12],[@R13]^

Ustekinumab is generally administered in a standard weight-dependent treatment regimen at week 0, 4, and every 12 weeks thereafter. Currently, limited evidence on therapeutic drug monitoring is available. With this study, we aim to determine whether ustekinumab serum trough concentrations, AUA and HLA-Cw6 status are associated with clinical response to identify potential tools for ustekinumab drug monitoring.

MATERIALS AND METHODS {#s2}
=====================

Participants {#s2-1}
------------

Patients were eligible if they were ≥18 years of age, suffering from plaque-type psoriasis, and treated with subcutaneous ustekinumab for a minimum of 16 weeks. Ustekinumab dosing and interval were generally administered in a standard weight-dependent treatment regimen (dose of 45 mg for patients \<100 kg and 90 mg for patients ≥100 kg) every 12 weeks. However, dosing and interval could be adjusted in case of treatment failure (based on clinical response, not on pharmacokinetic outcomes) according to daily clinical practice. Patients were recruited from different centers: The Ghent University Hospital and nonacademic affiliated hospitals in Belgium (cohort 1) and the Academic Medical Center and Radboud University Medical Center in the Netherlands (cohort 2 and 3). Patient recruitment started in January 2011 and ended in August 2015. Patient demographics \[age, sex, body mass index, disease duration, diagnosis of psoriatic arthritis, previous biologic treatment, disease severity at initiation of ustekinumab therapy (PASI baseline)\] and treatment characteristics \[ustekinumab dosing and concomitant use of methotrexate (MTX)\] were collected at study entry.

Serum Trough Concentrations, AUA, HLA-Cw6 Status, and Determination of Clinical Response {#s2-2}
----------------------------------------------------------------------------------------

At baseline, week 16, week 28, week 40, week 52, and/or ≥week 64, serum samples were collected to determine ustekinumab trough concentrations, AUA and HLA-Cw6 status, and PASI assessment was performed to determine clinical response.

The serum samples, obtained within 3 days before ustekinumab administration, were each centrifuged for 10 minutes at 1500*g*. Serum samples from cohort 1 and 3 were stored at −80 degrees, whereas samples of cohort 2 were kept at −20 degrees, until they were sent batchwise to the Laboratory for Monoclonal Therapeutics, Sanquin Diagnostic Services, Amsterdam, the Netherlands. Ustekinumab trough concentrations were determined using an enzyme-linked immunosorbent assay (ELISA). This assay is based on the principle that ustekinumab is captured through its ability to bind IL-12 and rabbit antiustekinumab for the detection of ustekinumab.^[@R14],[@R15]^ Results were reported in micrograms per milliliter (mcg/mL). Detection of AUA was performed through a radioimmunoassay, which measures specific high-avidity IgG antibodies against ustekinumab by an antigen-binding test. These results were converted into arbitrary units (AUs) per milliliter, with a cutoff value for positivity set at 12 AU/mL.^[@R16],[@R17]^

Serum samples to determine ustekinumab trough concentrations and the presence of AUA were collected from all study patients. In cohort 1, HLA-Cw6 status was determined additionally. Samples for HLA-Cw6 allele genotyping were stored at −80°C, and DNA was extracted from leukocytes with the Promega Kit (ReliaPrep Large Volume HT gDNA Isolation System; Promega, Madison, WI). Polymerase chain reaction was performed with allele-specific primers: 5′-TACTACAACCAGAGCGAGGA-3′ and 5′-GGTCGAGCCATACATCCA-3′. Results were interpreted as either positive or negative. All methods were performed according to the manufacturer\'s instructions.

To assess clinical response, PASI and mean change in PASI (ΔPASI) were obtained, and patients were classified as nonresponder (ΔPASI \<50.00%), moderate responder (ΔPASI 50.00%--74.99%), or good responder (ΔPASI 75.00%--100.00%).

Statistical Analysis {#s2-3}
--------------------

SPSS Statistics 22.0 (IBM, Armonk, NY) was used for the statistical analysis of all data. To compare baseline characteristics between the 3 cohorts and between subgroups of patients, a Fisher exact test was used for categorical variables and Mann--Whitney *U* or Kruskal--Wallis tests were used for continuous variables. The associations between serum trough concentrations, AUA, and clinical response were evaluated using a linear mixed model. To ensure results would not be influenced by transitioning from another biologic or concomitant use of MTX, these factors were accounted for. A Fisher exact test was used to compare clinical response between HLA-Cw6--positive and HLA-Cw6--negative patients. For each test, a *P* value \<0.05 was considered statistically significant.

Ethics {#s2-4}
------

Approval for this multicenter cohort study was obtained from the medical ethics committees of all participating hospitals, and all patients gave their written informed consent before participation. The study is being conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO) and other relevant guidelines, regulations, and acts.

RESULTS {#s3}
=======

Study Population {#s3-1}
----------------

Of 141 eligible patients, 2 patients refused participation, and 2 patients were excluded as these patients had isolated nail psoriasis. Consequently, 137 patients were included in the cohort (respectively, 62, 48, and 27 patients in cohort 1, 2, and 3). Table [1](#T1){ref-type="table"} demonstrates demographic characteristics, which were comparable between cohorts. Patients (69.1% male) had a high body mass index \[28.9 (± 6.1) kg/m^2^\], a mean disease duration of 23.6 ± 12.9 years, and a mean PASI of 14.2 ± 7.6 at initiation of ustekinumab treatment. Thirty patients (21.9%) were diagnosed with psoriatic arthritis, and most patients (76.8%) received other biologic treatment(s) before ustekinumab. Twenty-five of 137 patients (18.2%) did not receive the standard ustekinumab dosing and schedule. In these patients dosing was adjusted based on clinical response. Seven patients with a body weight of 93--99 kg received 90 mg, and 6 patients with a body weight of 101--105 kg received 45 mg. Twelve patients received ustekinumab every 10 weeks instead of every 12 (due to insufficient response).

###### 

Patient Demographics

![](tdm-41-634-g001)

In total, 43 patients (31.2%) were treated with ustekinumab 90 mg and 15 patients (10.9%) used MTX comedication.

Data on serum trough concentrations, AUA, and clinical response were collected in all study patients. Data were collected at a single time point in 77 patients and at repeated time points in 60 patients (in 28 patients at 2 time points and in 32 patients at 3 time points). Data were collected in 75 patients at week 16, in 64 patients at week 28, in 10 patients at week 40, in 42 patients at week 52, and in 38 patients after ≥64 weeks. Subsequently, during this study, 229 observations for serum trough concentrations, AUA, and clinical response were obtained. At week 16, week 28, week 40--52, and ≥64, 34.7, 32.8, 48.1, and 65.8% of patients achieved PASI 75, respectively.

Ustekinumab Serum Trough Concentrations {#s3-2}
---------------------------------------

The median (range) serum trough concentration was 0.3 mcg/mL (\<0.02--3.80). Four patients had undetectable serum trough concentrations (\<0.02) at week 16. At week 28, 40, 52, and ≥64 no undetectable serum trough concentrations were observed. No statistically significant difference in trough concentrations was observed for patients receiving 45 mg versus 90 mg, with median (range) values of 0.30 mcg/mL (\<0.02--3.60) and 0.40 (\<0.02--3.80) mcg/mL, respectively (*P* = 0.14). Patients who used MTX comedication (n = 15, 10.9% of study population; 26 observations) demonstrated ustekinumab trough concentrations similar to patients on ustekinumab monotherapy: 0.30 mcg/mL (\<0.02--3.60) and 0.30 mcg/mL (\<0.02--3.80), respectively (*P* = 0.95).

No statistically significant difference was found in serum trough concentrations between moderate to good responders and nonresponders \[median (range); 0.3 (\<0.02--3.80), 0.3 (\<0.02--3.60), and (\<0.02--1.96), respectively, *P* = 0.948; Fig [1](#F1){ref-type="fig"}\]. In addition, no significant correlation was found between ustekinumab trough levels and ∆PASI (*P* = 0.302).

![Box-and-whisker plot showing ustekinumab trough concentrations across response groups. No statistically significant difference in serum trough concentrations was found between nonresponders, moderate responders, and good responders (*P* = 0.948). The limits of the boxes represent the interquartile (IQ) range. The line in the boxes is the median. The whiskers extend from the upper and lower edge of the box to the highest and lowest values, which are no greater than 1.5 times the IQ range. The circles and asterisks indicate outliers (values between 1.5 and 3 times the IQ range) and extreme outliers (values more than 3 times the IQ range), respectively.](tdm-41-634-g002){#F1}

Development of AUA {#s3-3}
------------------

AUA were detected in 12 of 137 patients (8.7%). In 3 of these patients, AUA were cleared during the study. Two of these patients remained nonresponders, and 1 patient achieved a good clinical response when AUA were cleared. In the other patients AUA persisted during the study (n = 5) or the evolution of AUA status remained unknown (n = 4), out of which AUA status was only collected at a single time point (n = 3), or AUA were only detected at the final study observation (n = 1).

AUA were detected in 6 of 75 observations (8.0%) at week 16, in 7 of 64 observations (10.9%) at week 28, in 1 of 10 observations (10%) at week 40, in 4 of 42 observations (9.5%) at week 52, and in 0 of 38 observations (0.0%) after ≥64 weeks. The AUA titer in AUA-positive patients ranged from 22 to 320 AU/mL. Median (range) serum trough concentrations were significantly lower in antibody-positive patients compared with antibody-negative patients; 0.02 mcg/mL (\<0.02--0.20) versus 0.30 mcg/mL (\<0.02--3.80), respectively, (*P* \< 0.001). A good response was significantly more frequently achieved in AUA-negative patients compared with AUA-positive patients (44.1% versus 22.2%, *P* = 0.032), Figure [2](#F2){ref-type="fig"}.

![Clinical response according to AUA status. A good response was significantly more frequent achieved in AUA-negative patients compared with AUA-positive patients (44.1% versus 22.2%, *P* = 0.032).](tdm-41-634-g003){#F2}

In patients on MTX comedication, 1 of 15 patients (6.7%) developed AUA compared with 11 of 122 patients (9.0%) on ustekinumab monotherapy, with no statistically significant differences between groups (*P* = 0.77).

HLA-Cw6 Genotyping {#s3-4}
------------------

HLA-Cw6 status was determined in 61 of 137 patients (44.5% of study population). Prevalence of HLA-Cw6 positivity was 41%. Most of the demographic characteristics were comparable between HLA-Cw6--positive and HLA-Cw6--negative patients, except for age at onset of psoriasis and prevalence of psoriatic arthritis. HLA-Cw6--positive patients developed psoriasis at an earlier age (21.4 versus 31.6 years, *P* = 0.012), and the prevalence of psoriatic arthritis was higher (although not significant) in HLA-Cw6--negative patients (28.6 versus 8.3%, *P* = 0.098). No statistically significant difference in clinical response (assessed ≥16 weeks) between Cw6-positive and Cw6-negative patients could be demonstrated (*P* = 0.164), although on average, slightly better response rates in Cw6-positive patients were observed (Fig. [3](#F3){ref-type="fig"}).

![Clinical response according to HLA-Cw6 status. There was no statistically significant difference in response between HLA-Cw6--positive and HLA-Cw6--negative patients (*P* = 0.164).](tdm-41-634-g004){#F3}

DISCUSSION {#s4}
==========

The prevalence of AUA development was 8.7%, which is comparable with the prevalence rates reported in the current literature (1%--11%)^[@R9],[@R18]--[@R20]^ but much lower than observed for other biologics such as adalimumab and infliximab. AUA-positivity significantly reduced serum trough concentrations and impaired clinical response. These data are supported by previously reported findings suggesting a trend toward decreased treatment response with the formation of AUA.^[@R18],[@R21],[@R22]^

In this cohort, AUA did develop during the first 52 weeks of ustekinumab treatment. However, the number of observations obtained in the first year of ustekinumab treatment (n = 191) was higher compared with the number of observations obtained in patients \>1 year on ustekinumab treatment (n = 38), which might underestimate the prevalence of AUA formation after long-term ustekinumab treatment.

We did not find a significant association between ustekinumab serum trough concentrations and clinical response. This observation is in line with the findings of Menting et al.^[@R19]^ An optimal ustekinumab threshold trough concentration as suggested in other inflammatory diseases can therefore not yet be recommended. In a cohort study by Toro-Montecinos et al,^[@R23]^ maintenance trough concentrations of ustekinumab in Crohn disease above 4.5 mcg/mL at 26 weeks or later were identified to correspond to an optimal clinical effect.

In a small number of patients (1.7%) in our cohort, undetectable ustekinumab serum trough concentrations were measured. This could be partly explained by the presence of antidrug antibodies. Other factors that could have contributed to this include patient\'s nonadherence, total clearance of ustekinumab at the time of serum sample collection, or inadequate detection of serum trough concentrations in patients with severe and active psoriasis in which all ustekinumab is bound to IL-12 and IL-23.

For anti--tumor necrosis factor inhibitors, a significant association between immunomodulatory comedication (eg, MTX) and serum trough concentrations has been demonstrated in several studies.^[@R24]--[@R26]^ In our study, MTX comedication did not significantly impact ustekinumab serum concentrations, which might be partly due to the low incidence of AUA. However, results should be interpreted with caution due to the small number of patients on MTX comedication. The therapeutic impact of MTX in patients on ustekinumab needs to be confirmed by future studies with sufficient power.

In this cohort, we included patients treated with ustekinumab for a minimum of 16 weeks. More and more data arise showing that early pharmacokinetic drug measurements, that is, during induction phase, might be predictive for drug concentrations and clinical response on maintenance treatment. Recently, Wilkinson et al^[@R27]^ reported on a large adalimumab cohort of 544 psoriasis patients and demonstrated that early drug concentration measurements (obtained between 1 and 12 weeks) were predictive for clinical response at 6 months. Whether measurement of ustekinumab early in treatment will help to make strategic treatment decisions is currently unknown and will be a valuable topic for future research.

With regard to pharmacogenetic markers, HLA-Cw6 has been suggested to potentially predict clinical response in psoriasis patients on ustekinumab.^[@R28]--[@R31]^ We observed a slight increase in response to ustekinumab in HLA-Cw6--positive patients compared with HLA-Cw6--negative patients, but the differences were small and not statistically significant. Several studies have elaborated on single-nucleotide polymorphisms other than HLA-Cw6 and detected an association between some of these polymorphisms and response to ustekinumab treatment.^[@R31]--[@R33]^ These results will have to be further explored to assess whether pharmacogenetic markers can play a role in the prediction of response to ustekinumab.

Our study has some limitations. First, it is still not an extensive patient population, especially to draw conclusions on whether HLA-Cw6 status can predict clinical response. Second, not all possible factors that might influence treatment response to ustekinumab (eg, topical therapy and adherence) were considered. Third, the data were collected at different time points, and serial measurements were collected only in part of the patients (43.8%), which might impact the detection of, for example, AUA formation.

CONCLUSIONS {#s5}
===========

Based on available evidence and our study results, we conclude that there is currently overall insufficient evidence to support the use of serum trough concentrations or HLA-Cw6 status to guide treatment decisions in ustekinumab patients. Measurement of AUA in ustekinumab patients should be considered if treatment response is unsatisfactory.

Future research is needed to gain a better understanding on ustekinumab pharmacokinetics and pharmacodynamics and to identify additional tools for therapeutic drug monitoring in psoriasis patients on ustekinumab treatment.
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